| UNITED STATES | OMB APPROVAL |
| SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 | OMB Number: 3235-0060
Expires: January 31, 2008
Estimated average burden hours per response. . 38.0 |
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) June 16, 2006 (June 14, 2006)
ALLOS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 000-29815 | 54-1655029 |
(State or other jurisdiction | (Commission | (IRS Employer |
of incorporation) | File Number) | Identification No.) |
| | |
11080 CirclePoint Road, Suite 200 | |
Westminster, Colorado | 80020 |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (303) 426-6262
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
o | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
o | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
o | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events.
On June 14, 2006, Allos Therapeutics, Inc. (“Allos”) issued a press release announcing the publication of new findings from its Phase 3 REACH study of EFAPROXYN (efaproxiral) plus whole brain radiation therapy in patients with brain metastases from various primary cancers. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1 Press Release, dated June 14, 2006, entitled “Retrospective Analysis of Allos Therapeutics’ Phase 3 REACH Study Finds Positive Correlation between Patient Outcomes and EFAPROXYN(TM) (efaproxiral) Exposure in Patients with Brain Metastases from Breast and Non-Small Cell Lung Cancers”.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 16, 2006
| ALLOS THERAPEUTICS, INC. |
| | |
| By: | /s/ Marc H. Graboyes |
| | Marc H. Graboyes |
| Its: | Vice President, General Counsel |
3
